Jove
Visualize
Contáctanos
JoVE
x logofacebook logolinkedin logoyoutube logo
ACERCA DE JoVE
Visión GeneralLiderazgoBlogCentro de Ayuda JoVE
AUTORES
Proceso de PublicaciónConsejo EditorialAlcance y PolíticasRevisión por ParesPreguntas FrecuentesEnviar
BIBLIOTECARIOS
TestimoniosSuscripcionesAccesoRecursosConsejo Asesor de BibliotecasPreguntas Frecuentes
INVESTIGACIÓN
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchivo
EDUCACIÓN
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualCentro de Recursos para ProfesoresSitio de Profesores
Términos y Condiciones de Uso
Política de Privacidad
Políticas

Videos de Conceptos Relacionados

Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
Atherosclerosis I: Introduction01:30

Atherosclerosis I: Introduction

Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
Atherosclerosis II: Clinical Manifestations and Diagnostic Tests01:27

Atherosclerosis II: Clinical Manifestations and Diagnostic Tests

Atherosclerosis is a progressive disorder that leads to the thickening and narrowing of arterial walls due to plaque buildup. This condition can cause various symptoms depending on the arteries affected:Coronary Artery Disease (CAD): This condition affects the coronary arteries and may lead to chest pain (angina), shortness of breath (dyspnea), heart attacks, and other heart disease symptoms.Cerebrovascular Disease: This affects blood flow to the brain, causing transient ischemic attacks (TIAs)...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Peripheral Artery Disease I: Introduction01:30

Peripheral Artery Disease I: Introduction

Peripheral artery disease (PAD) predominantly results from atherosclerosis, which involves the accumulation of fatty deposits, or plaques, within the walls of arteries. This causes them to narrow and harden, significantly reducing blood flow. PAD predominantly affects the legs, particularly the arteries supplying the thighs and calves. In rare cases, it may involve other arteries, including those in the arms.Etiology of PAD:The principal cause of PAD is atherosclerosis, which results from fatty...

También podría leer

Artículos Relacionados

Artículos vinculados a este trabajo por autores compartidos, revista y gráfico de citas.

Ordenar por
Same author

Increasing incidence and changing trends in etiology & survival rates in HCC in a European cohort.

JHEP reports : innovation in hepatology·2026
Same author

Validated Early Detection Metrics Reduce the Population Requiring Liver Fibrosis Screening.

Gastroenterology·2026
Same author

Assessing Europe's policy readiness to confront the MASLD/MASH public health threat.

The Lancet regional health. Europe·2026
Same author

Metabolic Liver Disease Beyond the Liver: Association of Metabolic Dysfunction-Associated Steatotic Liver Disease with Cardiovascular and Renal Diseases.

Clinics in liver disease·2026
Same author

Updated Global Consensus Recommendations for Risk Stratification, Treatment Initiation, and Response Monitoring in Metabolic Dysfunction-Associated Steatotic Liver Disease.

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association·2026
Same author

Combination of quantitative MRI and laboratory markers for the detection and staging of metabolic dysfunction-associated steatotic liver disease.

European radiology·2026

Video Experimental Relacionado

Updated: May 23, 2026

A Model of Disturbed Flow-Induced Atherosclerosis in Mouse Carotid Artery by Partial Ligation and a Simple Method of RNA Isolation from Carotid Endothelium
11:00

A Model of Disturbed Flow-Induced Atherosclerosis in Mouse Carotid Artery by Partial Ligation and a Simple Method of RNA Isolation from Carotid Endothelium

Published on: June 23, 2010

La función LCAT comprometida se asocia con un aumento de la aterosclerosis.

G Kees Hovingh1, Barbara A Hutten, Adriaan G Holleboom

  • 1Department of Vascular Medicine, Academic Medical Center, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands.

Circulation
|August 3, 2005
PubMed
Resumen
Este resumen es generado por máquina.

Las personas con defectos del gen LCAT tienen un colesterol HDL bajo y triglicéridos altos, lo que aumenta el riesgo de enfermedades cardiovasculares. Dirigirse a LCAT puede ofrecer una nueva estrategia para la prevención de ECV.

Más Videos Relacionados

Quantitative Analysis and Characterization of Atherosclerotic Lesions in the Murine Aortic Sinus
06:43

Quantitative Analysis and Characterization of Atherosclerotic Lesions in the Murine Aortic Sinus

Published on: December 8, 2013

Quantification of Atherosclerosis in Mice
06:59

Quantification of Atherosclerosis in Mice

Published on: June 12, 2019

Videos de Experimentos Relacionados

Last Updated: May 23, 2026

A Model of Disturbed Flow-Induced Atherosclerosis in Mouse Carotid Artery by Partial Ligation and a Simple Method of RNA Isolation from Carotid Endothelium
11:00

A Model of Disturbed Flow-Induced Atherosclerosis in Mouse Carotid Artery by Partial Ligation and a Simple Method of RNA Isolation from Carotid Endothelium

Published on: June 23, 2010

Quantitative Analysis and Characterization of Atherosclerotic Lesions in the Murine Aortic Sinus
06:43

Quantitative Analysis and Characterization of Atherosclerotic Lesions in the Murine Aortic Sinus

Published on: December 8, 2013

Quantification of Atherosclerosis in Mice
06:59

Quantification of Atherosclerosis in Mice

Published on: June 12, 2019

Área de la Ciencia:

  • La bioquímica es la bioquímica.
  • Genética La genética.
  • Medicina Cardiovascular La medicina cardiovascular es una especialidad de la salud.

Sus antecedentes:

  • El colesterol HDL bajo es un factor de riesgo conocido para la enfermedad cardiovascular (ECV).
  • El papel del colesterol HDL severamente reducido, debido a las mutaciones del gen de la lecitina:colesterol aciltransferasa (LCAT), en el riesgo de ECV sigue sin estar claro.
  • Comprender el riesgo de ECV en los portadores de la mutación LCAT puede revelar LCAT como un objetivo terapéutico.

Objetivo del estudio:

  • Investigar la asociación entre las mutaciones del gen LCAT y los factores de riesgo cardiovascular.
  • Para evaluar los marcadores de riesgo cardiovascular en individuos con defectos en el gen LCAT.

Principales métodos:

  • Se evaluaron los lípidos, las lipoproteínas, la proteína C reactiva (CRP) y el grosor íntima-media de la arteria carótida (IMT).
  • Comparó 47 heterocigotos para mutaciones en el gen LCAT con 58 controles familiares.
  • Análisis estadístico ajustado por edad, género y consumo de alcohol.

Principales resultados:

  • Los heterocigotos mostraron una disminución del 36% en el colesterol HDL, un aumento del 23% en los triglicéridos y un aumento de 2,1 veces en la PCR.
  • La TMI carotídea se incrementó significativamente en los heterocigotos en comparación con los controles (P<0,0015 después del ajuste).

Conclusiones:

  • Los defectos del gen LCAT están relacionados con un colesterol HDL bajo, triglicéridos elevados y aumento de la PCR.
  • El aumento observado en el IMT sugiere que el LCAT protege contra la aterosclerosis.
  • Dirigirse a la LCAT para aumentar el colesterol HDL puede ser una estrategia viable para reducir el riesgo de ECV.